Stock DNA
Pharmaceuticals & Biotechnology
JPY 16,150 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.72
-154.70%
11.22
Total Returns (Price + Dividend) 
Oncolys BioPharma, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Oncolys BioPharma Hits Day High with Strong 7.06% Intraday Surge
Oncolys BioPharma, Inc. has seen a notable rise in stock performance, contrasting with a decline in the Japan Nikkei 225 index. Over the past week and month, the stock has shown significant gains, although long-term challenges persist, including a decline in five-year performance and negative financial metrics.
Read More
Oncolys BioPharma Hits Day High with 7.94% Surge in Stock Price
Oncolys BioPharma, Inc. has seen a notable increase in stock performance today, reaching an intraday high. While the company has achieved a significant year-to-date gain, its long-term performance reveals substantial declines. Additionally, it faces challenges such as negative return on equity and low operating profit growth.
Read More
Oncolys BioPharma Hits Day Low of JPY 774 Amid Price Pressure
Oncolys BioPharma, Inc. saw its stock price decline significantly today, reaching an intraday low amid a challenging trading environment. Despite a strong annual performance, the company's financial metrics reveal issues with management efficiency and negative earnings, raising concerns about its short-term stability in the biotechnology sector.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 38.20% vs -85.28% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -50.16% vs -93.55% in Dec 2023
YoY Growth in year ended Dec 2024 is 13.09% vs -68.73% in Dec 2023






